Vimta Labs Limited
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| VIMTALABS.BO | LH | ICLR | 603127.SS | BIM.PA | MEDP | |
|---|---|---|---|---|---|---|
| Market cap | 22.62B | 29.86B | 15.22B | 34.88B | 11.13B | 18.37B |
| P/E (TTM) | 29.2 | 30.1 | 81.2 | 30.4 | 24.2 | 36.5 |
| Forward P/E | 66.9 | 18.8 | 17.5 | 105.8 | 20.1 | 33.1 |
| Price/book | 4.6 | 3.4 | 1.7 | 3.7 | 2.6 | 31.4 |
| Dividend yield | 0.40% | 0.78% | — | 0.27% | 1.00% | — |
| 1-year change | −21.83% | +49.12% | +26.94% | +32.91% | −7.35% | +10.91% |
| Today | +1.45% | +3.92% | −0.32% | +5.56% | −3.17% | −1.01% |
The closest companies by business and industry (Diagnostics & Research). Prices may be delayed up to 15 min.
Latest news
All VIMTALABS.BO news ›Vimta Labs Q2 FY27 Total Income Jumps To ₹114.9 Crore, Half-Year Revenue Hits ₹227.8 Crore As Biologics Services Grow
Mumbai: Vimta Labs Limited on Thursday reported a total income of ₹114.9 crore for the second quarter of the financial year 2026-27, marking a 9.9% increase compared to ₹104.5 crore in the same period last year. The company's EBITDA for Q2…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- freepressjournal.in1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 1 articles, not a forecast.